Document is current
Any future updates will be listed below
-
Authors
Deng, Suqi https://orcid.org/0000-0001-7667-9695
Du, Juan https://orcid.org/0000-0003-4701-3573
Huang, Kexiu
Gale, Robert Peter
Pan, Danqi
Wang, Lu
Wei, Junjie
Zheng, Xue
Xu, Ying
Xie, Shengqian
Zhou, Wei
Xiao, Weihao
Liu, Bo
Chen, Zhiyang https://orcid.org/0009-0002-8460-2633
Ju, Zhenyu
Zeng, Hui https://orcid.org/0000-0002-4498-8888
-
Funding
Funding for this research was provided by:
Guangdong Science and Technology Department (2021B1515020017)
National Natural Science Foundation of China (82270167, 81970143)
- License Information
-
More Information
Article History
Received: 26 September 2023
Revised: 1 November 2024
Accepted: 7 November 2024
First Online: 18 November 2024
Competing interests
: RPG is a consultant to NexImmune Inc. Nanexa Pharma Ascentage Pharm Group and Antengene Biotech LLC, Medical Director of FFF Enterprises Inc.; Partner in AZCA Inc.; Board of Directors of Russian Foundation for Cancer Research Support and Scientific Advisory Board: StemRad Ltd.
: The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice guideline and received approval from the Ethics Committee of the First Affiliated Hospital of Jinan University (KY-2023-117) and is registered on clinicaltrials.gov (NCT05919199). Informed consent was obtained from all participants. All clinical data including PET/CT images and bone marrow samples were obtained and published after written informed consent. The experiments of PDX models were approved by the Institutional Animal Care and Use Committee of Jinan University (JNU-IACUC) and conformed to all relevant regulatory standards. Mice were kept in ventilated cages under pathogen-free conditions with 12 h light and dark cycle and given water and food ad libitum. All 18F-FDG experiments were conducted with the approvals mentioned above and with proper radiation protection.
